S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ALZN

Alzamend Neuro (ALZN) Stock Price, News & Analysis

$1.02
+0.02 (+2.00%)
(As of 03/27/2024 ET)
Today's Range
$0.96
$1.05
50-Day Range
$0.82
$1.20
52-Week Range
$0.74
$11.91
Volume
19,069 shs
Average Volume
53,980 shs
Market Capitalization
$7.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.50

Alzamend Neuro MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,105.9% Upside
$22.50 Price Target
Short Interest
Healthy
1.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Alzamend Neuro in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$5,100 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.32 out of 5 stars

ALZN stock logo

About Alzamend Neuro Stock (NASDAQ:ALZN)

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

ALZN Stock Price History

ALZN Stock News Headlines

Alzamend Neuro (NASDAQ:ALZN) Shares Down 1.6%
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Maxim gets more bearish on Alzamend Neuro, downgrades shares
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Alzamend Neuro Announces Reverse Stock Split
Alzamend Neuro, Inc. (9ZT0.F)
Alzamend Neuro CFO Katzoff buys 53K shares
See More Headlines
Receive ALZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/13/2023
Today
3/27/2024
Fiscal Year End
4/30/2024
Next Earnings (Estimated)
7/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALZN
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.50
High Stock Price Target
$22.50
Low Stock Price Target
$22.50
Potential Upside/Downside
+2,105.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.47 per share

Miscellaneous

Free Float
6,348,000
Market Cap
$7.26 million
Optionable
Optionable
Beta
-0.03
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Stephan Jackman (Age 47)
    CEO & Director
    Comp: $434.24k
  • Mr. David J. Katzoff (Age 61)
    Chief Financial Officer
    Comp: $116.67k
  • Mr. Milton Charles Ault III (Age 54)
    Founder & Vice Chairman
  • Mr. Henry C. W. Nisser Esq. (Age 54)
    Executive VP, General Counsel & Director
    Comp: $50k
  • Mr. Kenneth S. Cragun CPA (Age 63)
    Senior Vice President of Finance

ALZN Stock Analysis - Frequently Asked Questions

Should I buy or sell Alzamend Neuro stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alzamend Neuro in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALZN shares.
View ALZN analyst ratings
or view top-rated stocks.

What is Alzamend Neuro's stock price target for 2024?

1 Wall Street analysts have issued 12-month target prices for Alzamend Neuro's shares. Their ALZN share price targets range from $22.50 to $22.50. On average, they predict the company's share price to reach $22.50 in the next year. This suggests a possible upside of 2,105.9% from the stock's current price.
View analysts price targets for ALZN
or view top-rated stocks among Wall Street analysts.

How have ALZN shares performed in 2024?

Alzamend Neuro's stock was trading at $0.89 on January 1st, 2024. Since then, ALZN shares have increased by 14.6% and is now trading at $1.02.
View the best growth stocks for 2024 here
.

Are investors shorting Alzamend Neuro?

Alzamend Neuro saw a increase in short interest in March. As of March 15th, there was short interest totaling 51,200 shares, an increase of 13.0% from the February 29th total of 45,300 shares. Based on an average trading volume of 56,100 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.0% of the company's stock are sold short.
View Alzamend Neuro's Short Interest
.

When is Alzamend Neuro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our ALZN earnings forecast
.

How were Alzamend Neuro's earnings last quarter?

Alzamend Neuro, Inc. (NASDAQ:ALZN) posted its earnings results on Wednesday, September, 13th. The company reported ($0.60) earnings per share (EPS) for the quarter.

When did Alzamend Neuro's stock split?

Alzamend Neuro shares reverse split before market open on Tuesday, October 31st 2023. The 1-15 reverse split was announced on Tuesday, October 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Alzamend Neuro IPO?

Alzamend Neuro (ALZN) raised $12 million in an initial public offering (IPO) on Tuesday, June 15th 2021. The company issued 2,500,000 shares at $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager.

Who are Alzamend Neuro's major shareholders?

Alzamend Neuro's stock is owned by a number of institutional and retail investors. Top institutional investors include Truist Financial Corp (2.17%), Vanguard Group Inc. (1.10%), Vanguard Group Inc. (1.10%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David J Katzoff, L Mary Smith, Lynne Fahey Mcgrath, Mark Gustafson, Milton C Ault III, Milton C Ault III, Milton C Ault III and Stephan Jackman.
View institutional ownership trends
.

How do I buy shares of Alzamend Neuro?

Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALZN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners